- 221studies in the library match, of 33,380
- 69name it in the title
- 1987–2026years published
- 215peer-reviewed articles
The query: title or abstract mentions "anosmia", "hyposmia", "olfactory"/"olfaction", "smell" or "odour identification", matched case-insensitively against each record's title and abstract (its summary field) in alzhub's library of 33,380 study records, as of 2026-11-18. Every count on this page comes from that match. The matched list as JSON.
The olfactory bulb and the brain regions that process smell are among the first affected by Alzheimer's tau pathology, and also by the alpha-synuclein pathology of Parkinson's and Lewy body disease. Smell tests ask people to identify common odours from a set of choices; a low score is called hyposmia and a complete loss anosmia.
The research asks whether smell tests can flag people at risk before memory fails, how well they separate Alzheimer's from other causes, and whether they add anything to blood and imaging biomarkers. Smell also declines with normal ageing, nasal disease and viral infection, so a poor score on its own is not a diagnosis.
This page describes what published research in alzhub's library reports. It is not medical advice and does not apply to any one person. Only a doctor who knows the person's history can say what a result or a treatment means for them.
What the studies report, in their own words
Whole sentences copied from the abstract or key findings of the highest-scoring matched studies, chosen because they mention the subject and give a figure. 8 of the 221 matched records are quoted; each links to its study page and from there to the paper.
“Positivity was linked to older age at testing and self-reported olfactory impairment (P = 0.004), but not other demographic or cognitive features.”
“Participant mortality rate was 45% in the lowest quartile of UPSIT scores (anosmia) and 18% in the highest quartile of UPSIT scores.”
“The following diagnoses were also found to be associated with PD: sensory impairments beyond anosmia, such as hearing loss (OR, 1.14; 95% CI, 1.09-1.20) and changes of skin sensation (OR, 1.31; 95% CI, 1.21-1.43).”
“Advanced age (hazard ratio [HR] = 1.07), olfactory loss (HR = 2.8), abnormal color vision (HR = 3.1), subtle motor dysfunction (HR = 3.9), and nonuse of antidepressants (HR = 3.5) identified higher risk of disease conversion.”
“Results Of the 1630 participants who were cognitively normal at the time of the smell test, 33 died before follow-up and 167 were lost to follow-up.”
“In multivariate analyses, baseline age, University of Pennsylvania Smell Inventory Test (UPSIT) scores, CSF amyloid - (Aβ 42 ) to t-tau ratio, and APOE status were associated with change in MoCA scores over time.”
“Among isolated RBD patients with positive α-synuclein RT-QuIC, 78.6% had olfactory dysfunction compared to 21.4% with negative α-synuclein RT-QuIC (P < 0.001).”
“Olfaction and color vision were tested at baseline, then annually for 5 years.”
What kind of evidence it is
By study design
| Design (as recorded) | Studies |
|---|---|
| Systematic review or meta-analysis | 6 |
| Other clinical trial | 3 |
| Cohort or longitudinal study | 25 |
| Case-control study | 2 |
| Cross-sectional study | 10 |
| Other recorded design | 1 |
| No design recorded | 174 |
The design is the one named in alzhub's record for the study; a record with none is counted as "no design recorded".
By year
| Year | Studies | Share |
|---|---|---|
| 2026 | 8 | |
| 2025 | 19 | |
| 2024 | 9 | |
| 2023 | 8 | |
| 2022 | 13 | |
| 2021 | 11 | |
| 2020 | 5 | |
| 2019 | 10 | |
| 2018 | 3 | |
| 2017 | 13 | |
| 2016 and earlier | 122 |
Other counts within the matched set
| Peer-reviewed articles | 215 |
| Marked open access in the record | 52 |
| Rated "high" evidence strength in alzhub's summary | 8 |
| Rated "moderate" evidence strength in alzhub's summary | 41 |
| Rated "low" evidence strength in alzhub's summary | 170 |
| No evidence-strength rating | 2 |
| Records stating a participant count | 65 |
| Median participants (those records) | 113 |
| Largest participant count | 17,589 |
Within the 221 matched studies
| Studies… | Count | Rule |
|---|---|---|
| …that mention a smell identification test | 44 | the abstract also contains "UPSIT", "Sniffin'", "odour identification" or "smell test" |
| …that also mention mild cognitive impairment | 27 | the abstract also contains "MCI" or "mild cognitive impairment" |
| …that also mention Parkinson's or Lewy bodies | 101 | the abstract also contains "Parkinson" or "Lewy body" |
The 10 highest-scoring matched studies
Title matches first, then by alzhub's usefulness score, which rates a study's design, journal, evidence and recency, not whether its result is good news.
- Olfactory identification deficits and increased mortality in the community
- Association Between Olfactory Dysfunction and Amnestic Mild Cognitive Impairment and Alzheimer Disease Dementia
- Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder
- Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder
- Tau propagation in the brain olfactory circuits is associated with smell perception changes in aging
- Olfactory identification and incidence of mild cognitive impairment in older age
- Two-step detection of Lewy body pathology via smell-function testing and CSF α-synuclein seed amplification
- Odor identification as a biomarker of preclinical AD in older adults at risk
- Olfactory deficits predict cognitive decline and Alzheimer dementia in an urban community
- Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration
Systematic reviews and meta-analyses in the set
6 of the matched records are recorded as a systematic review, meta-analysis or umbrella review; the highest-scoring not already listed above:
- Sixty-Day Outcomes Among Patients Hospitalized With COVID-19
- A systematic review of neurological symptoms and complications of COVID-19
- Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease
- Possible association between PM2.5 and neurodegenerative diseases: A systematic review
- Emerging Putative Associations between Non-Coding RNAs and Protein-Coding Genes in Neuropathic Pain: Added Value from Reusing Microarray Data
Newest matched studies
- Neuroinflammation is an early pathological process in a mouse model of prodromal Parkinsons disease
- Alzheimer’s Disease-Associated Proteomic Changes in Olfactory Stem Cells Show Pathway-Level Transcriptomic Overlap
- Brain-wide Cerebrospinal Fluid Recirculation Collapse in Alzheimer’s Disease
- Early life social isolation primes flies for more rapid TDP-43 dependent neurodegeneration later in life
- Brain Iron Accumulation and Its Cognitive and Olfactory Correlates in Late-Life Depression
Journals with the most matched studies
| Journal | Studies |
|---|---|
| Journal of Alzheimer's disease : JAD | 12 |
| Neurology | 12 |
| Brain : a journal of neurology | 11 |
| Annals of neurology | 7 |
| Movement disorders : official journal of the Movement Disorder Society | 7 |
Questions
- Does losing your sense of smell mean Alzheimer's?
- No. Smell declines with age, colds, sinus disease, head injury and viral infections, and most people with a poor sense of smell do not develop dementia. The studies on this page test whether a low smell score adds information about risk when combined with other findings.
- How many studies on loss of smell and alzheimer's does alzhub hold?
- 221 of the 33,380 study records in alzhub's library match the query "title or abstract mentions "anosmia", "hyposmia", "olfactory"/"olfaction", "smell" or "odour identification"". Of these, 69 name it in the title. Counted from the records when this page was built.
- What kinds of study are they?
- 6 systematic review or meta-analysis, 3 other clinical trials, 25 cohort or longitudinal studys, 2 case-control studys, 10 cross-sectional studys; 174 record no design.
- What is the most recent study in the set?
- "Neuroinflammation is an early pathological process in a mouse model of prodromal Parkinsons disease" (bioRxiv, 2026), the newest by publication date among the matched records.
- Which journals publish most on it?
- Journal of Alzheimer's disease : JAD (12); Neurology (12); Brain : a journal of neurology (11), counted across the matched records.
Read on
- The 10 warning signsWhat early changes look like.
- MCI to dementia conversion rateWhat predicts progression.
- Getting a diagnosisWhat the diagnostic process involves.
Library subjects these studies are filed under
All answer pages → · What the library can and cannot answer →
Last updated